cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.13130/rd_unimi/rjrjox/gmhs4t
title: Maggio_1895_Pagina_001.jpg

description: Bulletin of 1895/05/01
DOI: 10.13130/rd_unimi/xu1sm0/ylachv
title: Giugno_1893_Pagina_054.jpg

description: Bulletin of 1893/06/14
DOI: 10.25934/pr00012345
title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Explore Changes in Subcutaneous Adipose Tissue and Modulation of Skin Inflammation After 12 Weeks of Treatment With Secukinumab, Compared to Placebo, and up to 52 Weeks of Treatment With Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis

description: This study provided a comparison of secukinumab to placebo with respect to skin inflammation as measured by skin exams in comparison to skin biopsies, adipose tissue and blood sample analyses.
DOI: 10.25934/pr00012346
title: A Randomized, Double-blind, Multicenter Study Assessing Short and Long-term Efficacy, Safety, and Tolerability of Sub-cutaneous Secukinumab in Subjects of Body Weight 90 kg or Higher With Moderate to Severe Chronic Plaque-type Psoriasis

description: The purpose of this study is to assess secukinumab high dose (every 2 weeks) vs standard dose (every 4 weeks) in heavy body weight subjects with moderate to severe plaque psoriasis.
DOI: 10.13130/rd_unimi/6np0bt/mibvzb
title: Giugno_1894_Pagina_038.jpg

description: Bulletin of 1894/06/10
DOI: 10.13130/rd_unimi/cbrkhv/ufzsym
title: Gennaio_1927_Pagina_070.jpg

description: Bulletin of 1927/01/18
DOI: 10.13130/rd_unimi/gsbgp1/pnz2ps
title: Giugno_1889_Pagina_095.jpg

description: Bulletin of 1889/06/24
DOI: 10.13130/rd_unimi/v8alup/y0wz1x
title: Giugno_1891_Pagina_077.jpg

description: Bulletin of 1891/06/20
DOI: 10.25934/pr00012347
title: Multicenter, rAndomized, Double-blind, Placebo-conTrolled, 52-week stUdy to demonstRatE the Efficacy, Safety and Tolerability of Secukinumab Injections With 2 mL Auto-injectors (300 mg) in Adult Subjects With Plaque Psoriasis

description: The primary purpose of this study is to assess efficacy, safety and tolerability of a 2 mL pre-filled auto-injector (AI) of 300 mg secukinumab in patients with moderate to severe plaque psoriasis
DOI: 10.3886/e241288v1
title: The Impact of Early Investments in Urban School Systems in the United States

description: This is the replication package for "The Impact of Early Investments in Urban School Systems in the United States" by Ethan Schmick and Allison Shertzer. The Journal of Economic History. Forthcoming.
DOI: 10.13130/rd_unimi/jvs9pt/tdjvsk
title: Giugno_1892_Pagina_053.jpg

description: Bulletin of 1892/06/14
DOI: 10.13130/rd_unimi/nsvbhr/b0oeyd
title: Giugno_1890_Pagina_080.jpg

description: Bulletin of 1890/06/20
DOI: 10.25574/03207
title: Chandra X-ray Observatory ObsId 03207

description: THE Z=1.786 CLUSTER AROUND 3C294
DOI: 10.25934/pr00012348
title: A Randomized, Controlled, Multicenter, Open-label Study With Blinded Assessment of the Efficacy of Subcutaneous Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Plaque Psoriasis.

description: This is a randomized, controlled, multicenter, open-label study with blinded assessment of the efficacy of subcutaneous secukinumab compared to Fumaderm®, in 200 adults with moderate to severe plaque type psoriasis who are candidates for systemic therapy. The study consists of 2 periods: a screening period of at least one week and up to four weeks, and a treatment period of 24 weeks. During the screening period eligibility of the patients is confirmed. Eligible patients are randomized 1:1 to treatment arm A or B at week 0. Patients in treatment arm A receive secukinumab administered at weeks 0, 1, 2, 3, 4, 8, 12, 16 and 20 and are followed up for assessments of the study endpoints until week 24. Patients in treatment arm B receive daily doses of Fumaderm® p.o.. Safety and efficacy measurements of secukinumab and Fumaderm® will be performed throughout the study and up to week 24.
DOI: 10.13130/rd_unimi/awv4gb/4r4d8l
title: Giugno_1896_Pagina_033.jpg

description: Bulletin of 1896/06/09
DOI: 10.13130/rd_unimi/rjrjox/axafk6
title: Luglio_1895_Pagina_113.jpg

description: Bulletin of 1895/07/29
DOI: 10.13130/rd_unimi/xu1sm0/ruuwgj
title: Giugno_1893_Pagina_055.jpg

description: Bulletin of 1893/06/14
DOI: 10.25934/pr00012349
title: A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs

description: The purpose of this study was to demonstrate the clinical efficacy, safety and tolerability of secukinumab compared to placebo in patients with nr-axSpA at Week 16 as well as Week 52 and long term efficacy and safety up to Week 104 (core phase) followed by an optional extension phase consisting of a 16-week randomized dose escalation treatment period and a continuous treatment period for up to Week 208
DOI: 10.13130/rd_unimi/6np0bt/61dtz6
title: Giugno_1894_Pagina_039.jpg

description: Bulletin of 1894/06/10
DOI: 10.13130/rd_unimi/cbrkhv/2jrfj6
title: Gennaio_1927_Pagina_071.jpg

description: Bulletin of 1927/01/18
DOI: 10.13130/rd_unimi/gsbgp1/nab2lr
title: Giugno_1889_Pagina_096.jpg

description: Bulletin of 1889/06/24
DOI: 10.25934/pr00012350
title: A 24-week, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Secukinumab in Controlling Spinal Pain in Patients With Axial Spondyloarthritis

description: The purpose of the study was to evaluate the efficacy and safety of secukinumab 150 mg compared to placebo in the early management (Baseline to Week 8) of spinal pain, disease activity, fatigue, and predictability of disease flares in patients with axial spondyloarthritis (axSpA) who had an inadequate response to prior non-steroidal anti-inflammatory drugs (NSAIDs). This study also explored the efficacy and safety of secukinumab 300 mg compared to secukinumab 150 mg from Week 8 to Week 24 in order to assess the potential additional benefits of dose escalation in patients with axSpA.
DOI: 10.13130/rd_unimi/awv4gb/u1wrry
title: Giugno_1896_Pagina_034.jpg

description: Bulletin of 1896/06/09
DOI: 10.13130/rd_unimi/nsvbhr/omktut
title: Giugno_1890_Pagina_081.jpg

description: Bulletin of 1890/06/21
DOI: 10.13130/rd_unimi/v8alup/id3voa
title: Giugno_1891_Pagina_078.jpg

description: Bulletin of 1891/06/20
DOI: 10.13130/rd_unimi/jvs9pt/c05kyw
title: Giugno_1892_Pagina_054.jpg

description: Bulletin of 1892/06/14
DOI: 10.13130/rd_unimi/xu1sm0/szu4hp
title: Giugno_1893_Pagina_056.jpg

description: Bulletin of 1893/06/14
DOI: 10.25574/03208
title: Chandra X-ray Observatory ObsId 03208

description: A SEARCH FOR X-RAY EMISSION FROM A PROTO-CLUSTER AT Z=3.8
DOI: 10.25934/pr00012351
title: A Phase 1, Randomized, Single Blind, Placebo Controlled, Single Ascending Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN PCSSC in Subjects With Elevated Low Density Lipoprotein Cholesterol

description: The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ALN-PCSSC in subjects with elevated LDL-C.
DOI: 10.25934/pr00012352
title: A 52-week, Open Label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750 - 2000 mg/d in the Treatment of Manic Episodes of Bipolar I Disorder.

description: This extension study is designed to investigate the long-term safety and tolerability of licarbazepine 750-2000 mg/d over 52 weeks in patients who completed the 6-week double-blind study CLIC477D2302.
DOI: 10.13130/rd_unimi/6np0bt/regpev
title: Giugno_1894_Pagina_040.jpg

description: Bulletin of 1894/06/10
DOI: 10.13130/rd_unimi/gsbgp1/kyllpb
title: Giugno_1889_Pagina_097.jpg

description: Bulletin of 1889/06/25
DOI: 10.13130/rd_unimi/rjrjox/lwgafh
title: Maggio_1895_Pagina_005.jpg

description: Bulletin of 1895/05/02
DOI: 10.25934/pr00012353
title: A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Licarbazepine 750 ¿ 2000 mg/d as Adjunctive Therapy to an Atypical Antipsychotic in the Treatment of Manic Episodes of Bipolar I Disorder Over 6 Weeks

description: The purpose of this study is to evaluate the effectiveness and tolerability of an investigational drug for the treatment of manic episodes of bipolar disorder. The investigational drug will be given as additional therapy to one of the five following medications: risperidone, olanzapine, quetiapine, ziprasidone, or aripiprazole. These medications are already FDA (Food and Drug Administration)-approved treatments for mania.
DOI: 10.13130/rd_unimi/cbrkhv/lcxnyk
title: Gennaio_1927_Pagina_072.jpg

description: Bulletin of 1927/01/18
DOI: 10.13130/rd_unimi/nsvbhr/zfjmog
title: Giugno_1890_Pagina_082.jpg

description: Bulletin of 1890/06/21
DOI: 10.13130/rd_unimi/v8alup/sxqanz
title: Giugno_1891_Pagina_079.jpg

description: Bulletin of 1891/06/20
DOI: 10.25574/03209
title: Chandra X-ray Observatory ObsId 03209

description: A DETAILED STUDY OF THE CORE OF THE PERSEUS CLUSTER
DOI: 10.25934/pr00012354
title: Study VEG108844, A Study of Pazopanib Versus Sunitinib in the Treatment of Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma

description: This was a randomized, open-label, parallel group Phase III non inferiority study to evaluate the efficacy and safety of pazopanib compared with sunitinib in subjects with advanced renal cell carcinoma (RCC) who had not received prior systemic therapy for advanced or metastatic RCC.
DOI: 10.13130/rd_unimi/awv4gb/c6dn0d
title: Giugno_1896_Pagina_035.jpg

description: Bulletin of 1896/06/09
DOI: 10.13130/rd_unimi/xu1sm0/dmj2nj
title: Giugno_1893_Pagina_057.jpg

description: Bulletin of 1893/06/15
DOI: 10.25934/pr00012355
title: A 26-week, Randomized, Double Blind, Parallel-group Multicenter Study to Assess the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD

description: This study will evaluate the efficacy and safety of QVA149 (110/50 μg o.d.) vs tiotropium (18 µg o.d.) + salmeterol/fluticasone propionate FDC (50/500 µg b.i.d.) in patients with moderate to severe COPD
DOI: 10.13130/rd_unimi/gsbgp1/xcb5ic
title: Giugno_1889_Pagina_098.jpg

description: Bulletin of 1889/06/25
DOI: 10.13130/rd_unimi/jvs9pt/zmglun
title: Giugno_1892_Pagina_055.jpg

description: Bulletin of 1892/06/14
DOI: 10.13130/rd_unimi/rjrjox/lssl4i
title: Luglio_1895_Pagina_115.jpg

description: Bulletin of 1895/07/29
DOI: 10.25934/pr00012356
title: A Randomized, Double-blind, Parallel-group, 26-week Study Comparing the Efficacy and Safety of Indacaterol (Onbrez® Breezhaler® 150 mcg o.d.) With Salmeterol/Fluticasone Propionate (Seretide® Accuhaler® 50 mcg/500 mcg b.i.d.) in Patients With Moderate Chronic Obstructive Pulmonary Disease

description: The purpose of this study is to compare the effectiveness and safety of indacaterol with salmeterol /fluticasone propionate treatment in patients with moderate chronic obstructive pulmonary disease who, on entry to the study are being treated with salmeterol /fluticasone propionate.
DOI: 10.13130/rd_unimi/6np0bt/oc4ior
title: Giugno_1894_Pagina_041.jpg

description: Bulletin of 1894/06/11
DOI: 10.13130/rd_unimi/cbrkhv/ts0gk0
title: Gennaio_1927_Pagina_073.jpg

description: Bulletin of 1927/01/19
DOI: 10.13130/rd_unimi/nsvbhr/ugmjui
title: Giugno_1890_Pagina_083.jpg

description: Bulletin of 1890/06/21
DOI: 10.25574/03210
title: Chandra X-ray Observatory ObsId 03210

description: CLUSTER DARK MATTER ON THE SMALLEST SCALES
DOI: 10.25934/pr00012357
title: A Randomized, Multicentre, Open-Label, Phase III Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Anthracycline- or Taxane-Exposed ErbB2-Positive Metastatic Breast Cancer

description: This open label study was designed to evaluate Lapatinib effect on incidence of brain metastases in ErbB2 (HER2) positive metastatic breast cancer patients exposed to prior taxanes or anthracyclines.
DOI: 10.13130/rd_unimi/jvs9pt/fgmxzn
title: Giugno_1892_Pagina_056.jpg

description: Bulletin of 1892/06/14
DOI: 10.13130/rd_unimi/v8alup/hmzqd0
title: Giugno_1891_Pagina_080.jpg

description: Bulletin of 1891/06/20
DOI: 10.13130/rd_unimi/xu1sm0/rwuokk
title: Giugno_1893_Pagina_058.jpg

description: Bulletin of 1893/06/15
DOI: 10.25934/pr00012358
title: RAINBOW Study: a Randomized, Controlled Study Evaluating the Efficacy and Safety of RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity

description: The purpose of this study was to determine if intravitreal ranibizumab is superior to laser ablation therapy in the treatment of retinopathy of prematurity (ROP).
DOI: 10.13130/rd_unimi/awv4gb/hv4txq
title: Giugno_1896_Pagina_036.jpg

description: Bulletin of 1896/06/09
DOI: 10.13130/rd_unimi/rjrjox/cerh8q
title: Maggio_1895_Pagina_009.jpg

description: Bulletin of 1895/05/03
DOI: 10.25934/pr00012359
title: A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients (NYHA Class II-IV) With Preserved Ejection Fraction (PARAGON-HF)

description: The purpose of this study was to evaluate the effect of LCZ696 compared to valsartan in the reduction of cardiovascular death and heart failure(HF) hospitalizations in patients with HF with preserved ejection fraction.
DOI: 10.13130/rd_unimi/6np0bt/mv7snt
title: Giugno_1894_Pagina_042.jpg

description: Bulletin of 1894/06/11
DOI: 10.13130/rd_unimi/cbrkhv/6b7hm5
title: Gennaio_1927_Pagina_074.jpg

description: Bulletin of 1927/01/19
DOI: 10.13130/rd_unimi/gsbgp1/caaju2
title: Giugno_1889_Pagina_099.jpg

description: Bulletin of 1889/06/25
DOI: 10.13130/rd_unimi/nsvbhr/tw5lx5
title: Giugno_1890_Pagina_084.jpg

description: Bulletin of 1890/06/21
DOI: 10.25574/03211
title: Chandra X-ray Observatory ObsId 03211

description: COMPLEX CLUSTERS: MERGERS AND NARROW ANGLE TAILED RADIO SOURCES
DOI: 10.25934/pr00012360
title: A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis

description: This study was to provide 24 - 52 week efficacy, safety and tolerability data to support the registration of the secukinumab (AIN457) prefilled syringe (PFS) for subcutaneous self administration in subjects with active PsA despite current or previous NSAID, DMARD and/or anti-TNFα therapy. An additional 4 years of long-term efficacy and safety data were collected during the post Week 52 period of the study.
DOI: 10.13130/rd_unimi/jvs9pt/x7c0ch
title: Giugno_1892_Pagina_057.jpg

description: Bulletin of 1892/06/15
DOI: 10.13130/rd_unimi/v8alup/oayxpp
title: Giugno_1891_Pagina_081.jpg

description: Bulletin of 1891/06/21
DOI: 10.25934/pr00012361
title: A Randomized, Double-blind, Placebo-controlled Phase III Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Efficacy at 16 Weeks and to Assess Long-term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Ankylosing Spondylitis

description: This study assessed the efficacy and safety of secukinumab in patients with active ankylosing spondylitis who were tolerant to or had an inadequate response to NSAIDs, DMARDs and / or TNFα inhibitor
DOI: 10.13130/rd_unimi/awv4gb/bx7lxf
title: Giugno_1896_Pagina_037.jpg

description: Bulletin of 1896/06/10
DOI: 10.13130/rd_unimi/rjrjox/i3nod8
title: Maggio_1895_Pagina_010.jpg

description: Bulletin of 1895/05/03
DOI: 10.13130/rd_unimi/xu1sm0/ftqfko
title: Giugno_1893_Pagina_059.jpg

description: Bulletin of 1893/06/15
DOI: 10.25934/pr00012362
title: A Randomized, Double-blind, Placebo-controlled Phase III Study of Secukinumab to Demonstrate the Efficacy at 16 Weeks and to Assess the Long-term Safety, Tolerability and Efficacy up to 3 Years in Subjects With Active Ankylosing Spondylitis

description: The purpose of this study was to generate 16-week efficacy data, as well as up to 3-year efficacy, safety and tolerability data in subjects with active AS despite current or previous NSAID, DMARD and/or anti-TNF therapy.
DOI: 10.13130/rd_unimi/6np0bt/bhj9yc
title: Giugno_1894_Pagina_043.jpg

description: Bulletin of 1894/06/11
DOI: 10.13130/rd_unimi/gsbgp1/rxz44c
title: Giugno_1889_Pagina_100.jpg

description: Bulletin of 1889/06/25
DOI: 10.13130/rd_unimi/nsvbhr/cku9g6
title: Giugno_1890_Pagina_085.jpg

description: Bulletin of 1890/06/22
DOI: 10.15468/dl.fm4ang
title: Occurrence Download

description: A dataset containing 7676 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Neuroterus anthracinus"
 ]
}

 The dataset includes 7676 records from 90 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0054865-251120083545085/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.25574/03212
title: Chandra X-ray Observatory ObsId 03212

description: THE X-RAY STRUCTURE OF OLD, HIGH LUMINOSITY FOSSIL GALAXY GROUPS
DOI: 10.25934/pr00012363
title: A Three-part Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Secukinumab Treatment in Juvenile Idiopathic Arthritis Subtypes of Psoriatic and Enthesitis-related Arthritis

description: This was a double-blind, placebo-controlled, event-driven randomized withdrawal study to investigate the efficacy and safety of secukinumab treatment in the Juvenile Idiopathic Arthritis (JIA) categories of Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA). The study was divided into 3 parts (plus a post-treatment follow-up period) consisting of open-label, single-arm active treatment in Treatment Periods 1 and 3 and a randomized, double-blind, placebo controlled, event-driven withdrawal design in Treatment Period 2
DOI: 10.13130/rd_unimi/cbrkhv/uw24kv
title: Gennaio_1927_Pagina_075.jpg

description: Bulletin of 1927/01/19
DOI: 10.13130/rd_unimi/jvs9pt/wbbwzj
title: Giugno_1892_Pagina_058.jpg

description: Bulletin of 1892/06/15
DOI: 10.13130/rd_unimi/v8alup/2jmidz
title: Giugno_1891_Pagina_082.jpg

description: Bulletin of 1891/06/21
DOI: 10.25934/pr00012364
title: A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia

description: This was a single arm, open-label, multi-center, phase II study to determine the efficacy and safety of an experimental therapy called CTL019 T-cells in pediatric patients with B-cell acute lymphoblastic leukemia, who were refractory to standard chemotherapy regimen or relapsed after allogeneic stem cell transplant.
DOI: 10.25934/pr00012365
title: A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP

description: Main Study (CACZ885M2301): The purpose of the pivotal phase of this trial was to test the hypothesis that canakinumab treatment of patients with myocardial infarction (MI) at least one month prior to study entry and elevated hsCRP could prevent recurrent cardiovascular events.The purpose of the extension phase of the main study is to collect additional long-term safety data on continued exposure to canakinumab in patients who participated in the pivotal phase.Sub-study 1 (CACZ885M2301S1): The purpose of this sub-study was to evaluate the effect of quarterly subcutaneous canakinumab treatment for 24 months comparted with placebo on the carotid plaque burden measured by integrated vascular MRI in patients enrolled in the CACZ885M2301 study (CANTOS).Sub-study 2 (CACZ885M2301S2): The purpose of this CANTOS sub-study was to determine whether, in patients with type 2 diabetes participating in the CANTOS main study, canakinumab compared to placebo, on top of standard of care could increase insulin secretion and insulin sensitivity.
DOI: 10.13130/rd_unimi/awv4gb/u49yax
title: Giugno_1896_Pagina_038.jpg

description: Bulletin of 1896/06/10
DOI: 10.13130/rd_unimi/rjrjox/q4klrs
title: Luglio_1895_Pagina_120.jpg

description: Bulletin of 1895/07/30
DOI: 10.13130/rd_unimi/xu1sm0/qb7lsv
title: Giugno_1893_Pagina_060.jpg

description: Bulletin of 1893/06/15
DOI: 10.25934/pr00012366
title: A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients

description: The primary purpose of this study is to demonstrate pharmacokinetic bioequivalence of ofatumumab injected by Pre-filled Syringe (PFS) versus Auto-Injector (AI) devices and thereby establish a bridge between the ongoing Phase 3 program and the to-be-marketed drug-device combinations
DOI: 10.13130/rd_unimi/6np0bt/mjlnil
title: Giugno_1894_Pagina_044.jpg

description: Bulletin of 1894/06/11
DOI: 10.13130/rd_unimi/gsbgp1/gxq4kp
title: Giugno_1889_Pagina_101.jpg

description: Bulletin of 1889/06/26
DOI: 10.25574/03213
title: Chandra X-ray Observatory ObsId 03213

description: THE X-RAY STRUCTURE OF OLD, HIGH LUMINOSITY FOSSIL GALAXY GROUPS
DOI: 10.25934/pr00012367
title: A Randomized, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients With Relapsing Multiple Sclerosis

description: To compare the efficacy and safety of ofatumumab administered subcutaneously (sc) every 4 weeks versus teriflunomide administered orally once daily in patients with relapsing multiple sclerosis
DOI: 10.13130/rd_unimi/jvs9pt/lbxrfi
title: Giugno_1892_Pagina_059.jpg

description: Bulletin of 1892/06/15
DOI: 10.13130/rd_unimi/nsvbhr/0haquf
title: Giugno_1890_Pagina_086.jpg

description: Bulletin of 1890/06/22
DOI: 10.13130/rd_unimi/v8alup/7rbsxr
title: Giugno_1891_Pagina_083.jpg

description: Bulletin of 1891/06/21
DOI: 10.13130/rd_unimi/6np0bt/dv2pfm
title: Giugno_1894_Pagina_045.jpg

description: Bulletin of 1894/06/12
DOI: 10.13130/rd_unimi/awv4gb/9jbc8z
title: Giugno_1896_Pagina_039.jpg

description: Bulletin of 1896/06/10
DOI: 10.13130/rd_unimi/cbrkhv/sttrxd
title: Gennaio_1927_Pagina_076.jpg

description: Bulletin of 1927/01/19
DOI: 10.13130/rd_unimi/xu1sm0/cuklee
title: Giugno_1893_Pagina_061.jpg

description: Bulletin of 1893/06/16
DOI: 10.25934/pr00012368
title: A Randomized, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients With Relapsing Multiple Sclerosis.

description: To compare the efficacy and safety of ofatumumab administered subcutaneously (sc) every 4 weeks versus teriflunomide administered orally once daily in patients with relapsing multiple sclerosis
DOI: 10.13130/rd_unimi/rjrjox/5zljyi
title: Maggio_1895_Pagina_012.jpg

description: Bulletin of 1895/05/03
DOI: 10.25574/03214
title: Chandra X-ray Observatory ObsId 03214

description: THE X-RAY STRUCTURE OF OLD, HIGH LUMINOSITY FOSSIL GALAXY GROUPS
DOI: 10.25934/pr00012369
title: A Phase III Randomized Open-label Multi-center Study of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation

description: Assess the efficacy and safety of ruxolitinib compared to Best Available Therapy (BAT) in patients with corticosteroid-refractory acute graft vs. host disease (aGvHD) after allogeneic stem cell transplantation.
DOI: 10.13130/rd_unimi/gsbgp1/4dnxmc
title: Giugno_1889_Pagina_102.jpg

description: Bulletin of 1889/06/26
DOI: 10.13130/rd_unimi/jvs9pt/yytju0
title: Giugno_1892_Pagina_060.jpg

description: Bulletin of 1892/06/15